BDX

Becton Dickinson and Co

Add to Watchlist

Advanced Chart

178.850

-2.05(-1.133%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

181.600

Open

181.500

VWAP

179.31

Vol

3.47M

Mkt Cap

51.26B

Low

177.960

Amount

622.32M

EV/EBITDA(TTM)

13.67

Total Shares

289.01M

69.85B

EV/OCF(TTM)

20.96

P/S(TTM)

2.49

Becton, Dickinson and Company is a global medical technology company. The Company is engaged in the development, manufacture and sale of a broad range of medical supplies, devices, laboratory equipment and diagnostic products used by healthcare institutions, physicians, life science researchers, clinical laboratories, and more. Its BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings. The BD Medical segment consists of various business units, including medication delivery solutions, medication management solutions, advanced monitoring, and pharmaceutical systems. Its BD Life Sciences segment provides products for the collection and transport of diagnostics specimens, and instruments and reagent systems to detect a range of infectious diseases, healthcare-associated infections and cancers. Its BD Interventional segment provides vascular, urology, oncology and surgical specialty products.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q3

FY2025Q4

FY2026Q1

5.49B

+8.56%

3.410

-2.56%

5.87B

+8.02%

3.994

+4.83%

5.37B

+3.86%

3.249

-5.26%

Estimates Revision

The market is revising Upward the revenue expectations for Becton, Dickinson and Company (BDX) for FY2025, with the revenue forecasts being adjusted by 0.07% over the past three months. During the same period, the stock price has changed by -9.03%.

Revenue Estimates for FY2025

Revise Upward

+0.07%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-1.33%

In Past 3 Month

Stock Price

Go Down

-9.03%

In Past 3 Month

13 Analyst Rating

12.83% Upside

Wall Street analysts forecast BDX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BDX is 201.80 USD with a low forecast of 172.00 USD and a high forecast of 255.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

4 Buy

9 Hold

0 Sell

Moderate Buy

12.83% Upside

Current: 178.850

Low

172.00

Averages

201.80

High

255.00

12.83% Upside

Current: 178.850

Low

172.00

Averages

201.80

High

255.00

Barclays

Matt Miksic

Overweight

downgrade

$261 -> $241

2025-06-03

Reason

Barclays

Matt Miksic

Price Target

$261 -> $241

2025-06-03

downgrade

Overweight

Reason

Barclays analyst Matt Miksic lowered the firm's price target on Becton Dickinson to $241 from $261 and keeps an Overweight rating on the shares. The firm revised earnings estimates to be in-line with management's outlook.

Citi

Buy

Neutral

downgrade

$185

2025-05-22

Reason

Citi

Price Target

$185

2025-05-22

downgrade

Buy

Neutral

Reason

Citi downgraded Becton Dickinson to Neutral from Buy with an $185 price target.

Citi

Buy -> Neutral

downgrade

$217 -> $185

2025-05-22

Reason

Citi

Price Target

$217 -> $185

2025-05-22

downgrade

Buy -> Neutral

Reason

Piper Sandler

Jason Bednar

Buy

Maintains

$280 → $260

2025-04-23

Reason

Piper Sandler

Jason Bednar

Price Target

$280 → $260

2025-04-23

Maintains

Buy

Reason

Piper Sandler analyst Jason Bednar lowered the firm's price target on Becton Dickinson to $260 from $280 and keeps an Overweight rating on the shares ahead of quarterly results. The firm notes that policy and broad economic uncertainty has seemingly created opportunities for investors to do value shopping, with Becton Dickinson (BDX) and Sotera Health (SHC) looking best positioned to respond favorably to upcoming reports when considering current sentiment/positioning.

Barclays

Travis Steed

Buy

Maintains

$279 → $261

2025-04-07

Reason

Barclays

Travis Steed

Price Target

$279 → $261

2025-04-07

Maintains

Buy

Reason

Barclays lowered the firm's price target on Becton Dickinson to $261 from $279 and keeps an Overweight rating on the shares. The firm updated its sum-of-the-parts analysis following reports that the company plans to separate its Bioscience and Diagnostics Solutions business. It cites a drop in peer multiples for the target cut.

Barclays

Travis Steed

Buy

Maintains

$278 → $279

2025-02-14

Reason

Barclays

Travis Steed

Price Target

$278 → $279

2025-02-14

Maintains

Buy

Reason

Barclays raised the firm's price target on Becton Dickinson to $279 from $278 and keeps an Overweight rating on the shares. The firm says its updated sum-of-the-parts valuation analysis suggests 19% upside to Becton from current levels, based on an updated model estimates and several changes to assumptions.

See All Ratings

Valuation Metrics

The current forward P/E ratio for Becton Dickinson and Co (BDX.N) is 12.64, compared to its 5-year average forward P/E of 19.39. For a more detailed relative valuation and DCF analysis to assess Becton Dickinson and Co 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

Strongly Undervalued

5Y Average PE

19.39

Current PE

12.64

Overvalued PE

22.09

Undervalued PE

16.70

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

Strongly Undervalued

5Y Average EV/EBITDA

15.26

Current EV/EBITDA

10.90

Overvalued EV/EBITDA

17.08

Undervalued EV/EBITDA

13.43

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Strongly Undervalued

5Y Average PS

3.51

Current PS

2.30

Overvalued PS

3.92

Undervalued PS

3.10

Financials

Annual

Quarterly

FY2025Q2

YoY :

+4.50%

5.27B

Total Revenue

FY2025Q2

YoY :

-23.00%

646.00M

Operating Profit

FY2025Q2

YoY :

-42.64%

308.00M

Net Income after Tax

FY2025Q2

YoY :

-42.16%

1.07

EPS - Diluted

FY2025Q2

YoY :

-90.79%

35.00M

Free Cash Flow

FY2025Q2

YoY :

-6.26%

42.81

Gross Profit Margin - %

FY2025Q2

YoY :

-45.11%

5.84

Net Margin - %

FY2025Q2

YoY :

+16.41%

4.61

ROIC

Trading Trends

Insider

Insiders areSelling! The selling amount has increased 111.23% over the last month.

Sold

0-3

Months

199.6K

USD

3-6

Months

796.0K

USD

6-9

Months

3.0M

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

350.4K

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Hedge Fund

Hedge Funds areBuying! The buying amount has increased 956.9% over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

1.3M

Volume

6-9

Months

536.0K

Volume

0-12

Months

0.0

Volume

Bought

0-3

0.0

Volume

Months

3-6

3.2M

Volume

Months

6-9

298.7K

Volume

Months

0-12

0.0

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

81.0K

USD

6-9

Months

0.0

USD

0-12

Months

8.0K

USD

Bought

0-3

48.0K

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Insider

Insiders areSelling! The selling amount has increased 111.23% over the last month.

Sold

0-3

Months

199.6K

USD

3-6

Months

796.0K

USD

6-9

Months

3.0M

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

350.4K

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

BDX News & Events

Events Timeline

2025-07-14 (ET)

2025-07-14

10:29:20

Leerink says Waters to bank on disciplined execution in longer run after deal

2025-07-14

10:21:24

Waters, BD Bioscience deal 'looks to be a good fit,' says Stifel

2025-07-14

09:01:58

Waters sinks 12% to $312.06 following combination with Becton unit

News

8.5

07-15WSJ

Waters Corp. Deal for Becton Dickinson Unit a Long-Term Play With Some Risks

8.5

07-15PRnewswire

Waters und der Geschäftsbereich Biosciences & Diagnostic Solutions von BD fusionieren und schaffen ein führendes Unternehmen für Biowissenschaften und Diagnostik, das sich auf regulierte, hochvolumige Tests konzentriert

8.5

07-15PRnewswire

Regroupement de Waters et de la division Biosciences & Diagnostic Solutions de BD, Création d'un leader des sciences de la vie et du diagnostic axé sur les tests réglementés à haut volume